Pfizer’s breast cancer drug approved two months early by FDA

Diagnostic Imaging Services shares a news story regarding early approval by the Food & Drug Administration (FDA) for promising breast cancer drug.

Pfizer Inc.’s drug Ibrance was approved for advanced breast cancer by U.S. regulators more than two months ahead of schedule, letting the drugmaker proceed with one of its most promising new blockbusters.

Pfizer estimated Ibrance could be an option for treatment in as many as 22,000 women a year who have advanced ER-positive, HER2-negative breast cancer. The company will charge $9,850 for a month’s supply of the drug before any discounts.